Jun 1, 2026 08:00AM
Jun 1, 2026 08:00AM
May 11, 2026 04:01PM
May 4, 2026 06:01AM
May 4, 2026 06:01AM
Mar 31, 2026 06:43AM
Mar 30, 2026 07:00AM Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Nov 20, 2025 08:00PM
Nov 20, 2025 08:00PM
Nov 13, 2025 07:00AM
Aug 13, 2025 07:00AM
May 28, 2025 06:45AM
May 23, 2025 04:09AM
May 15, 2025 06:01AM Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
Apr 2, 2025 07:03AM
Apr 2, 2025 07:00AM
Mar 25, 2025 06:48AM
Mar 24, 2025 04:01PM
Mar 4, 2025 06:44AM
Mar 3, 2025 07:01AM
Mar 3, 2025 07:00AM Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urolo
Nov 12, 2024 04:05PM
Oct 18, 2024 08:17AM
Sep 13, 2024 06:43AM
Sep 12, 2024 06:30AM
Sep 12, 2024 06:30AM
Sep 3, 2024 04:05PM
Aug 26, 2024 04:05PM Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanom
Aug 8, 2024 07:00AM
May 23, 2024 08:00AM
May 9, 2024 07:00AM
Mar 27, 2024 07:00AM
Dec 7, 2023 08:00AM
Nov 9, 2023 04:05PM
Nov 6, 2023 03:00PM Aura Biosciences (AURA) Receives FDA Agreement Under Special Protocol Assessment for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan
Nov 6, 2023 03:00PM
Aug 9, 2023 07:00AM
May 11, 2023 04:10PM
Mar 15, 2023 04:10PM
Nov 10, 2022 07:00AM
Oct 4, 2022 07:06AM
Oct 4, 2022 07:05AM Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
Oct 3, 2022 07:03AM
Oct 3, 2022 07:00AM
Sep 28, 2022 07:00AM
Aug 11, 2022 04:15PM
Jun 30, 2022 07:01AM
Jun 30, 2022 07:00AM
May 12, 2022 04:15PM Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Mar 21, 2022 07:03AM

322,218 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All